 Home > Biochemistry News > Biotechnology News > Over 1.3 billion U.S. dollars to develop a new generation of bispecific antibody therapy Janssen reached cooperation

Over 1.3 billion U.S. dollars to develop a new generation of bispecific antibody therapy Janssen reached cooperation

 Last Update: 2021-11-03
 Source: Internet
 Author: User

Tags

lupus antibody test

easy products sell

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 20, 2021, F-star Therapeutics announced that it has reached a licensing and cooperation agreement with Janssen Biotech, a subsidiary of Johnson & Johnson

F-star's Fcab platform can transform the Fc region of natural antibodies to introduce two additional different antigen binding sites

▲The Fcab platform can add 2 antigen binding sites in the Fc region of natural antibodies (picture source: F-star official website)

mAb2 works through 3 mechanisms:

1) Crosslinking: Bring together two different cells, or two receptors on the same cell, to activate the immune system

2) Clustering: clustering receptors on the cell surface to activate key immune cell pathways

3) Conditionality: Prevent immune cells from being activated by healthy cells

▲Three mechanisms of action of the quadrivalent bispecific antibody mAb2 (picture source: F-star official website)

According to the terms of the agreement, F-star is entitled to an upfront payment of US$17.

Reference materials:

[1] F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.